Ann: Q&A with Nativ Segev, MGC Pharmaceuticals Managing Director-MXC.AX, page-4

"Additionally, we are putting out a paper soon that provides a wide look at all clinical studies that have taken place globally using cannabis as the active ingredient. This will give doctors, legislators and researchers a place to start when figuring out the actual implementation of a Cannabis regime here in Australia."

"What should investors be on the lookout for in the next few months?
Many things are going to happen in the next few months, from international operations to the home market, as we are placing the Australian Strategy into motion including commercial regulation and educational programs.
MXC will enter into multinational clinical research in Oncological patients, severe epilepsy and other conditions, moving forward with its Dermatological OTC research as we recently announced with our cbd patch tests for acne and psoriasis conditions in Slovenia. Furthermore, we see an increase in our product lines and market opportunities, and we will increase our cultivation farms to support these operations."

Sounds like they have a good and clear vision and path towards marketisation and revenue production! Looking forward to these announcements to come.